Ionis (IONS), Biogen Down on Ending Development of ALS Drug

Shares of Ionis Pharmaceuticals (IONS) and Biogen (BIIB) lost at least 2% in market cap on Thursday after the companies announced their decision to terminate the development of their investigational amyotrophic lateral sclerosis (ALS) drug, BIIB105 / ION541. This decision was based on topline data from the phase I/II ALSpire study, wherein treatment with the drug did not slow disease progression. This was evident from the six-month data from the study wherein ALS patients treated with BIIB105 did not achiev ...